Business context and reporting period
Entity discrepancy: The supplied filing is for Oculus Innovative Sciences, Inc. and subsidiaries, not Sonoma Pharmaceuticals, Inc. Investors should verify the issuer before relying on this summary. The unaudited Form 10-Q covers the quarter and nine months ended December 31, 2011 (Oculus fiscal Q3 and year to date; fiscal year ends March 31). Dollar amounts below are in millions unless stated otherwise.
Oculus develops, manufactures, and markets Microcyn-based wound and tissue-care products, alongside laboratory testing services. U.S. products had seven FDA 510(k) clearances for device uses, but the company lacked U.S. clearance to market antimicrobial or wound-healing drug claims.
Financial performance and position
- Revenue: Q3 revenue was $2.790, up 21% from $2.313. Product revenue rose 30% to $2.597; service revenue declined to $0.193 from $0.310. Nine-month revenue was $9.393, up 33% from $7.043, principally reflecting product growth.
- Gross profit and margins: Q3 gross profit was $1.852 versus $1.149; nine-month gross profit was $6.579 versus $4.211. Overall gross margin was approximately 66% in Q3 and 70% for nine months, compared with approximately 50% and 60%, respectively, in the prior-year periods. Management reported Microcyn product gross margins of 71% and 75% for Q3 and nine months, respectively.
- Operating costs and losses: Q3 operating expenses increased to $4.206 from $3.227, and operating loss widened to $2.354 from $2.078. Q3 net loss was $2.547 ($0.09 per share), versus $2.230 ($0.08 per share). Nine-month operating loss improved to $5.002 from $6.119, and net loss improved to $5.561 from $6.254 ($0.21 versus $0.24 per share).
- Cash flow: Nine-month operating cash use was $2.718, down from $4.355 in the prior year. Investing cash use was $0.225; financing provided $3.581, including $2.500 of debt proceeds and $1.894 net equity proceeds, offset partly by $0.865 of debt repayments. Cash increased $0.590 to $4.961 from March 31, 2011.
- Liquidity and debt: Working capital was $3.784 at December 31, 2011; current assets were $8.172 and current liabilities $4.388. Long-term debt, net of debt discount, was $2.290 and current debt, net, was $0.944. The company also reported a $2.000 put warrant liability. The VLL6 loan was secured by company assets, including intellectual property, carried a 10% cash interest rate, and included warrant-related put rights.
- Other balance-sheet measures: Total assets were $8.981, total liabilities $8.818, and stockholders’ equity $0.163. Accumulated deficit was $130.546. Common shares outstanding were 28,855,729 at December 31, 2011.
Material changes versus prior periods
- U.S. product revenue increased 111% in Q3 and 72% year to date, aided by sales growth and an increase in the Innovacyn royalty rate from approximately 19% to 30% effective July 1, 2011. Mexico product revenue increased 8% in Q3 and 23% year to date; Europe and rest-of-world revenue declined 5% in Q3 but increased 21% year to date.
- Product margins improved across reported segments. Selling, general and administrative expense rose 34% in Q3 and 13% year to date; management attributed increases in part to stock-based compensation and sales costs. Research and development expense also increased.
- Q3 net loss worsened despite higher revenue and gross profit, as operating expenses and interest expense rose. Nine-month net loss improved, with operating-loss reduction partly offset by higher interest and other expense.
- Stock-based compensation was $2.339 for the nine months, compared with $1.839 in the prior year, and was a significant non-cash expense.
Outlook, risks, contingencies, and unusual items
- Management expected cash and cash equivalents to fund working-capital needs and sales, marketing, and R&D through at least January 1, 2013. It expected continued losses and said additional financing may be needed; no new financing commitment was secured. If capital is unavailable, the company may curtail R&D and reduce costs.
- Management expected R&D costs to rise over the next few quarters for testing, clinical trials, and product development, and SG&A to grow slightly as sales efforts expand. U.S. pivotal trials for drug commercialization were to be delayed pending a strategic partner or other funding; the timing was uncertain.
- In December 2011, the company initiated a voluntary Class II recall of select product lots due to labeling issues following FDA notification. It reported no safety or product-quality complaints, nominal recall costs, and no sales restrictions other than label revisions; management did not expect a material revenue impact.
- The company disclosed a Mexican lawsuit alleging, among other claims, conversion of assets, tortious interference, and defamation. Management considered it without merit and intended to defend the case; no loss reserve was recorded. The filing also discusses potential Mexican tax exposure relating to former distributor Quimica Pasteur; management believed a loss was unlikely but could not assure that no material loss would occur.
- One customer accounted for 24% of Q3 revenue and 25% of nine-month revenue. Three customers represented 14%, 13%, and 11% of accounts receivable at December 31.
- Subsequent to quarter-end, Nasdaq notified the company that it failed the $35 million minimum market value of listed securities requirement. It had until August 6, 2012 to regain compliance; failure could lead to delisting proceedings. The letter did not immediately affect trading.
- Other notable items include the December equity offering of 1,809,653 shares at $1.15 per share ($1.894 net proceeds), and a January 2012 grant of a 40,000-share option to a director for consulting services.
Most important facts for investors to verify
- Confirm the issuer: this filing identifies Oculus Innovative Sciences, Inc., not Sonoma Pharmaceuticals, Inc.
- Assess cash runway against ongoing operating cash burn, expected losses, and the January 1, 2013 liquidity estimate; verify access to additional financing.
- Review debt terms, collateral, amortization, effective interest costs, and the $2.000 put warrant liability, including potential cash obligations.
- Test whether product revenue growth and improved gross margins can offset rising SG&A, R&D, and interest expense, especially given customer concentration and the increased Innovacyn royalty rate.
- Track U.S. regulatory progress, funding and timing for pivotal trials, and any consequences from the product-labeling recall.
- Monitor the Mexican litigation and potential tax-related exposure, and the company’s progress toward Nasdaq listing compliance by August 6, 2012.